Literature DB >> 24674944

Herbal medicines for the treatment of functional and inflammatory bowel disorders.

Gerald Holtmann1, Nicholas J Talley2.   

Abstract

In many parts of the world, there continues to be a long-standing tradition of prescribing herbal products for a range of gastrointestinal conditions. Scientific evidence supporting the use of all herbal preparations is imperfect, however, and available studies are plagued by methodological limitations. For functional gastrointestinal disorders, there is limited evidence supporting the use of some well-characterized preparations. A number of herbals have immunomodulatory activity, and in inflammatory bowel disease there are limited positive placebo-controlled trials; other studies used active controls with suboptimal doses of the comparators. Like all drugs, herbals can lead to serious adverse events (eg, hepatic failure). Quality control is a serious issue to consider when prescribing herbal medicines. Many herbal preparations are marketed without evidence for stringent adherence to good manufacturing practice guidelines. Unpredictable environmental conditions may affect the composition and the concentration of the active ingredients of plant extracts. Further, commercial herbal products usually combine a variable plethora of chemical families with possible medicinal utility. While some of these ingredients might be of benefit, the concentration and dose of these constituents needs to be closely monitored. Physicians and regulators need to remain very cautious about the use of herbal remedies. Appropriate scientific evidence for the claimed clinical benefits should become mandatory worldwide, and the standards for production and safety monitoring should comply with established standards for chemically defined products. If these principles were adopted, the full value of herbal remedies may come to light, particularly as the individually bioactive compounds present in these preparations become recognized.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Functional Dyspepsia; Gastrointestinal; Herbal Medicine; Inflammatory Bowel Disease; Irritable Bowel Syndrome

Mesh:

Substances:

Year:  2014        PMID: 24674944     DOI: 10.1016/j.cgh.2014.03.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

Review 2.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

Review 3.  Functional dyspepsia.

Authors:  Nicholas J Talley; Thomas Goodsall; Michael Potter
Journal:  Aust Prescr       Date:  2017-12-04

Review 4.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

Review 5.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

6.  Treatment of functional dyspepsia and gastroparesis.

Authors:  Benjamin Stein; Kelley K Everhart; Brian E Lacy
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

Review 7.  Functional dyspepsia: new insights into pathogenesis and therapy.

Authors:  Nicholas J Talley
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

Review 8.  Functional Dyspepsia: Advances in Diagnosis and Therapy.

Authors:  Nicholas J Talley
Journal:  Gut Liver       Date:  2017-05-15       Impact factor: 4.519

9.  Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial.

Authors:  Felix Alt; Pee-Win Chong; Emily Teng; Ralf Uebelhack
Journal:  Phytother Res       Date:  2017-05-16       Impact factor: 5.878

Review 10.  Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease.

Authors:  Bei Yue; Zhi-Lun Yu; Cheng Lv; Xiao-Long Geng; Zheng-Tao Wang; Wei Dou
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.